Normal view MARC view ISBD view

A clinical guide to the management of Graves' disease with radioactive iodine.

MedStar author(s):

Citation: Endocrine Practice. 1(3):205-12, 1995 May-Jun.PMID: 15251595Institution: MedStar Washington Hospital CenterDepartment: Medicine/EndocrinologyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: IN PROCESS -- NOT YET INDEXEDYear: 1995 ISSN:

1530-891X

Name of journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsAbstract: More than 50 years have passed since radioactive iodine (RAI) was initially demonstrated as a therapeutic modality for the treatment of Graves' Disease. Today, more than a million patients have been treated with RAI. RAI is considered safe and highly effective. Its side-effect profile, ease of administration, and relative cost make RAI the treatment of choice for Graves' Disease of thyroidologists in this country. Questions continue to be raised as to which patients will benefit most from RAI therapy. Marked differences still exist between the practice preferences of thyroidologists as to whom, when, and how to treat with RAI. Factors that influence patient selection for RAI include age, the presence of pre-existing ophthalmopathy, lifestyle, history of previous treatment failure, and goiter size. Treatment goals, dosimetry, use of thionamides prior to therapy, safety recommendations following therapy, and prophylactic therapy with glucocorticoids for patients with ophthalmopathy highlight are some of the controversial issues facing the endocrinologist treating Graves' Disease with RAI. This symposium article reviews the current management of Graves' Disease with RAI.All authors: Levetan C, Wartofsky LFiscal year: FY1995Date added to catalog: 2021-02-18

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	15251595	Available		15251595

More than 50 years have passed since radioactive iodine (RAI) was initially demonstrated as a therapeutic modality for the treatment of Graves' Disease. Today, more than a million patients have been treated with RAI. RAI is considered safe and highly effective. Its side-effect profile, ease of administration, and relative cost make RAI the treatment of choice for Graves' Disease of thyroidologists in this country. Questions continue to be raised as to which patients will benefit most from RAI therapy. Marked differences still exist between the practice preferences of thyroidologists as to whom, when, and how to treat with RAI. Factors that influence patient selection for RAI include age, the presence of pre-existing ophthalmopathy, lifestyle, history of previous treatment failure, and goiter size. Treatment goals, dosimetry, use of thionamides prior to therapy, safety recommendations following therapy, and prophylactic therapy with glucocorticoids for patients with ophthalmopathy highlight are some of the controversial issues facing the endocrinologist treating Graves' Disease with RAI. This symposium article reviews the current management of Graves' Disease with RAI.

English